Laurus Labs Limited (LAURUSLABS) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,454 (+3.54% day change)
Key ratios
- P/E ratio
- 149
- P/B ratio
- 10.11
- ROE (%)
- 16.77
- ROCE (%)
- 18.87
- Debt/Equity
- 0.48
- Dividend yield (%)
- 0.16
- Market cap (₹ Cr)
- 132,592.56
Forensic checks
Piotroski F-Score: 8/9 · Altman Z-Score: 5.92 · Beneish M-Score: -2.77
InvestSights quality score
64/100 — Above Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q1 FY26)
AI summary: The single most important signal from Laurus Labs' Q1 FY26 concall is the structural shift in the company's revenue and margin profile, driven by an accelerating CDMO business that now contributes over 30% of revenues and is explicitly targeted to reach 50% over the medium term. The 31% YoY revenue growth to ₹1,570 crores, combined with gross margins expanding to ~59% and…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.